BR132016015841E2 - recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use - Google Patents

recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use Download PDF

Info

Publication number
BR132016015841E2
BR132016015841E2 BR132016015841A BR132016015841A BR132016015841E2 BR 132016015841 E2 BR132016015841 E2 BR 132016015841E2 BR 132016015841 A BR132016015841 A BR 132016015841A BR 132016015841 A BR132016015841 A BR 132016015841A BR 132016015841 E2 BR132016015841 E2 BR 132016015841E2
Authority
BR
Brazil
Prior art keywords
pcv
vaccine formulations
porcine circovirus
recombinant antigens
antigens
Prior art date
Application number
BR132016015841A
Other languages
Portuguese (pt)
Inventor
Abelardo Silva
Juliana Lopes Rangel Fietto
Rafael Locatelli SALGADO
Thiago Souza ONOFRE
Mariana Costa FAUSTO
Pedro Marcus Pereira Vidigal
Sthefany Patareli KALKS
Josicelli Souza CRISPIM
Roberta AMAZILES SILVA LEITE
Jackson De Andrade Teixeira
Natália FIALHO GONZAGA
Tiago Jaquel Zilch
Luiz Fernando Lino De Souza
Amanda Martins Da Cruz Souza
Antônio DE MORAIS MONTEIRO
Gustavo Costa BRESSAN
Márcia Rogéria De Almeida Lamêgo
Original Assignee
Universidade Federal de Viçosa
Fundação de Amparo à Pesquisa do Estado de Minas Gerais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal de Viçosa, Fundação de Amparo à Pesquisa do Estado de Minas Gerais filed Critical Universidade Federal de Viçosa
Priority to BR132016015841A priority Critical patent/BR132016015841E2/en
Publication of BR132016015841E2 publication Critical patent/BR132016015841E2/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais e uso. o presente certificado de adição se refere à obtenção do antígeno recombinante do capsídeo viral do porcine circovirus 2 (pcv-2) e suas modificações, mediante expressão em sistema procariótico, recuperação de partículas semelhantes a vírus (vlps) e sua utilização em formulações vacinais. os antígenos e as formulações vacinais podem ser empregados na imunização de animais em programas de controle das doenças associadas ao pcv-2 nos sistemas de produção de suínos convencionais e representam alternativas às vacinas disponíveis no mercado.recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use. this certificate of addition refers to obtaining the recombinant antigen from the viral capsid of the porcine circovirus 2 (pcv-2) and its modifications, through expression in a prokaryotic system, recovery of virus-like particles (vlps) and its use in vaccine formulations. antigens and vaccine formulations can be used to immunize animals in disease control programs associated with pcv-2 in conventional swine production systems and represent alternatives to vaccines available on the market.

BR132016015841A 2016-07-07 2016-07-07 recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use BR132016015841E2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR132016015841A BR132016015841E2 (en) 2016-07-07 2016-07-07 recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR132016015841A BR132016015841E2 (en) 2016-07-07 2016-07-07 recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use

Publications (1)

Publication Number Publication Date
BR132016015841E2 true BR132016015841E2 (en) 2020-04-07

Family

ID=70157959

Family Applications (1)

Application Number Title Priority Date Filing Date
BR132016015841A BR132016015841E2 (en) 2016-07-07 2016-07-07 recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use

Country Status (1)

Country Link
BR (1) BR132016015841E2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898435A (en) * 2021-01-14 2021-06-04 山西农业大学 Soluble fusion protein DT390-Cap as well as preparation method and application thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112898435A (en) * 2021-01-14 2021-06-04 山西农业大学 Soluble fusion protein DT390-Cap as well as preparation method and application thereof

Similar Documents

Publication Publication Date Title
BR102013001893A8 (en) porcine circovirus 2 (pcv-2) recombinant antigens for vaccine formulations, diagnostic kit and use
Robinson et al. Global Foot‐and‐Mouth Disease Research Update and Gap Analysis: 3‐Vaccines
EA202091513A1 (en) VACCINES AGAINST HEPATITIS B VIRUS (HBV) AND THEIR APPLICATION
BR112016019525A2 (en) uspa2 protein constructs and their use
EA201990718A1 (en) VECTORS OF Adenovirus of dogs
CY1118573T1 (en) USE OF A MODIFIED EYEVOLOGY VIRUS FOR EXTREMELY DEFECTS ANTI-VOLUME OR OTHER INVESTIGATIVE FACTORS
Lee et al. Progress and hurdles in the development of influenza virus-like particle vaccines for veterinary use
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
Kortekaas et al. Rift Valley fever vaccine development, progress and constraints
Lambe Novel viral vectored vaccines for the prevention of influenza
BR112016028418A2 (en) adjuvant composition, vaccine, cd40 agonist antibody or a part thereof, pharmaceutical composition, construct, cell, and epitope mapping method of a polypeptide
HRP20230752T1 (en) Foot-and-mouth disease vaccine
AR108014A1 (en) UNIVERSAL VACCINE FOR VIRAL DISEASES AND VACCINATION METHOD
BR112017027895A2 (en) recombinant viral vectors containing minor prrsv proteins and methods of manufacturing and using these
BR132016015841E2 (en) recombinant antigens from porcine circovirus 2 (pcv-2) for vaccine formulations and use
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
van de Sandt et al. Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine
Hernandez et al. Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs
Kondakova et al. Rotavirus vaccines: new strategies and approaches
Tabynov et al. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza
AR101256A1 (en) VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES
JP2019506168A5 (en)
MX2022007217A (en) Epitopic vaccine for african swine fever virus.
HUA et al. Advance in human papillomavirus major capsid protein L1-based vaccines
BR112023018838A2 (en) VACCINE COMPOSITIONS AND METHODS FOR USE THEREOF

Legal Events

Date Code Title Description
B03A Publication of an application: publication of a patent application or of a certificate of addition of invention
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07K 14/01 , A61K 39/012 , A61K 31/20 , C12N 15/34 , C12R 1/93 , G01N 33/569

Ipc: C07K 14/01 (2006.01), A61K 39/12 (2006.01), A61P 3